CA2916970A1 - Un compose mimetique smac destine au traitement des maladies proliferatives - Google Patents

Un compose mimetique smac destine au traitement des maladies proliferatives Download PDF

Info

Publication number
CA2916970A1
CA2916970A1 CA2916970A CA2916970A CA2916970A1 CA 2916970 A1 CA2916970 A1 CA 2916970A1 CA 2916970 A CA2916970 A CA 2916970A CA 2916970 A CA2916970 A CA 2916970A CA 2916970 A1 CA2916970 A1 CA 2916970A1
Authority
CA
Canada
Prior art keywords
cancer
patient
smac mimetic
tumors
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2916970A
Other languages
English (en)
Inventor
Stephen J. Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmascience Inc
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Priority to CA2916970A priority Critical patent/CA2916970A1/fr
Priority to PCT/CA2017/050019 priority patent/WO2017117684A1/fr
Publication of CA2916970A1 publication Critical patent/CA2916970A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2916970A 2016-01-08 2016-01-08 Un compose mimetique smac destine au traitement des maladies proliferatives Abandoned CA2916970A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA2916970A CA2916970A1 (fr) 2016-01-08 2016-01-08 Un compose mimetique smac destine au traitement des maladies proliferatives
PCT/CA2017/050019 WO2017117684A1 (fr) 2016-01-08 2017-01-06 Composé mimétique de smac pour utilisation dans le traitement de maladies prolifératives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2916970A CA2916970A1 (fr) 2016-01-08 2016-01-08 Un compose mimetique smac destine au traitement des maladies proliferatives

Publications (1)

Publication Number Publication Date
CA2916970A1 true CA2916970A1 (fr) 2017-07-08

Family

ID=59270788

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2916970A Abandoned CA2916970A1 (fr) 2016-01-08 2016-01-08 Un compose mimetique smac destine au traitement des maladies proliferatives

Country Status (2)

Country Link
CA (1) CA2916970A1 (fr)
WO (1) WO2017117684A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111918667A (zh) * 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法
CN112425560A (zh) * 2020-10-27 2021-03-02 纳肽得有限公司 皮肤增生性瘢痕动物模型及其构建方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886842A1 (fr) 2018-11-26 2021-10-06 Debiopharm International SA Traitement combiné d'infections au vih
CA3151770A1 (fr) 2019-09-25 2021-04-01 Silvano BRIENZA Schemas posologiques pour le traitement de patients presentant un carcinome localement avance des cellules squameuses
US20230233691A1 (en) 2021-10-22 2023-07-27 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111918667A (zh) * 2018-02-05 2020-11-10 特沙诺有限公司 儿科尼拉帕尼配制剂和儿科治疗方法
CN112425560A (zh) * 2020-10-27 2021-03-02 纳肽得有限公司 皮肤增生性瘢痕动物模型及其构建方法

Also Published As

Publication number Publication date
WO2017117684A1 (fr) 2017-07-13

Similar Documents

Publication Publication Date Title
CA2916970A1 (fr) Un compose mimetique smac destine au traitement des maladies proliferatives
JP6712427B2 (ja) 移植片対宿主病を処置し予防する方法
ES2763318T3 (es) Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas
US11116756B2 (en) Methods of treating pancreatic cancer
ES2608656T3 (es) Inhibidores de quinasa de punto de control 1 para la potenciación de agentes que dañan el ADN
AU2016362830B2 (en) Cytarabine conjugates for cancer therapy
AU2017345720B2 (en) Terlipressin compositions and their methods of use
EP2760446A1 (fr) Mimétique de smac (birinapant) à utiliser dans le traitement de maladies de prolifération (cancer)
EP3771469A1 (fr) Formulations et dosages pour l'administration d'un composé inhibant la protéine mcl1
CN114224889A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
AU2006334306A1 (en) Combination comprising combretastatin and anticancer agents
US20220324986A1 (en) Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
KR20130118981A (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
ES2864767T3 (es) Composición que comprende cenicriviroc y ácido fumárico para su uso en el tratamiento de lesiones hepáticas agudas o peritonitis
WO2014121178A1 (fr) Procédé de traitement par mimétique de smac
WO2023107706A1 (fr) Agents de dégradation de stat3 et leurs utilisations
US20150313963A1 (en) Treatment of cellular proliferative disorders
KR20210136252A (ko) 항종양 면역 상승효과를 나타내는 종양세포 특이적 자가조립 나노입자
US20230029336A1 (en) Combination Therapy for Treating a Hematological Malignancy
US20160296574A1 (en) Ephedra alata extracts and methods of use thereof
KR20220121793A (ko) 이식편대숙주 질환의 예방 또는 치료에 있어서의 화합물의 용도

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20190108